<DOC>
	<DOCNO>NCT00863772</DOCNO>
	<brief_summary>Tanezumab reduce pain osteoarthritis without affect nerve impulse transmit sensory nerve .</brief_summary>
	<brief_title>Tanezumab Nerve Function In Arthritis Patients</brief_title>
	<detailed_description>This study terminate 16 Nov 2010 follow US FDA clinical hold tanezumab osteoarthritis clinical study halt dose enrollment patient 23 June 2010 potential safety issue .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<criteria>BMI le equal 39 kg/m2 Osteoarthritis ( arthritis ) knee hip pain score qualifies Willing comply study visit schedule study requirement , include , woman childbearing potential male patient female partner childbearing potential , use 2 form birth control , one barrier method . Patients must consent write participate study . Untreated , uncontrolled disease , Unwilling unable discontinue use prohibit medication , include pain medication , screen period study , Significant cardiac disease within past 6 month Significant neurological disease ( e.g . peripheral neuropathy , multiple sclerosis , stroke ) sign neuropathy screen Known bleed disorder anticoagulation therapy Planned surgery study period History alcoholism drug abuse past 2 year Unable use acetaminophen Use biologic ( include live vaccine , exception Flumist ) within past 3 month Allergic reaction biologic antibody past Disqualifying laboratory value , include Hepatitis B C , HIV drug test Cancer past 5 year . Basal cell squamous cell carcinoma okay . Medical condition may interfere study endpoint safety subject determine investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>